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Abstract
There are approximately from 1,100 to 1,200 HIV-infected children in a follow-up in Spain. In 2008 an open,
multicentral, retrospective and prospective Cohort of the Spanish Paediatric HIV Network (CoRISpe) was founded.
The CoRISpe is divided into the node 1 and node 2 representing geographically almost the whole territory of Spain.
Since 2008 seventy-five hospitals have been participating in the CoRISpe. All the retrospective data of the
HIV-infected children have been kept in the CoRISpe since 1995 and prospective data since 2008. In this article we
are going to present the notion of CoRISpe, its role, the structure, how the CoRISpe works and the process how a
child is transferred from Paediatric to Adults Units.
The main objective of the CoRISpe is to contribute to furthering scientific knowledge on paediatric HIV infection by
providing demographic, sociopsychological, clinical and laboratory data from HIV-infected paediatric patients. Its
aim is to enable high-quality research studies on HIV-infected children.
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Background
Current treatment to prevent mother-to-child transmis-
sion (MTCT) of HIV is very different from that a few
years ago [1]. In the first years of HIV infection there were
not treatments for HIV-infected children [2,3]. In the
years from 1985 to 1996 children were treated with mono-
therapy or combination therapy [4]. Since then, highly
active antiretroviral therapy (HAART) has been used
[5-9]. Spain has had free general access to HAART since
1996. By the end of 2011 there have been around from
1,000 to 1,200 children diagnosed with HIV, all of them
infected through MTCT. Vertically HIV-infected children
have unique significance because the HIV infection takes
place in immature immune and nervous systems, which is
of particular interest to researchers [10-12].
A treatment immediately used after the birth has made
a tremendous difference to the HIV-infected children.
At the present moment it is not known how the HAART
era will affect the health and the survival of these chil-
dren [13]. Today HIV-infected infants and children sur-
vive to adolescence and adulthood. The challenge of
providing HIV care involves both acute and chronic, life-
long care. Families and health providers are interested in
all aspects of child’s progress and how HIV may affect
her/his performance in everyday tasks. In Spain the first
HIV-infected child was diagnosed in 1980. At present he
is 32 years old [14].
There is no the National Registry of HIV-infected
children and adults in Spain. The only Registry, which
exists, is the National Registry of AIDS. The main
objective of the Cohort of the Spanish Paediatric HIV
Network (CoRISpe) is to contribute to furthering scien-
tific knowledge on paediatric HIV infection by providing
the demographic (the country of birth, nationality of the
parents, the date of birth, the date of diagnosis, the day
of death, sex, race, etc), sociopsychological (educational
level of parents, foster parents, social status of the childs
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family, etc), clinical (HIV-progression, different illness
related to HIV infection, the percentage and absolute
number of CD4 and CD8, the level of plasma viral load,
etc) and laboratory data (the level of cholesterol, trigly-
cerides, transaminases, leucocytes, limphocytes, etc). Its
aim is to enable high-quality research studies on HIV-
infected children.
The role of the CoRISpe
The CoRISpe was founded in 2008 and was set up in
accordance with the Spanish official law on protection
of personal data [15]. We would like to emphasize the
fact that it is difficult to find an electronic database
(CoRISpe) containing demographic, sociopsychological,
clinical and laboratory data of HIV-infected children na-
tionally, mainly because these children are widely
spread in various cities and are taken care of by different
paediatricians. At the moment there are 84 hospitals
with HIV-infected children in Spain and 75 of these
hospitals are included in the CoRISpe representing
geographically almost the entire territory of Spain (the
highest number of HIV-infected children can be
seen in Catalonia, Madrid Community and Andalusia;
Figure 1A). These hospitals are responsible for entering
the dataset into the electronic database. Retrospective
data have been collected since 1995 and prospective
data since 2008. There are only 7 hospitals, which treat
HIV-1 infected children not included in the CoRISpe.
To obtain a database of high quality we contact all
paediatricians in Spain, and explain the objectives of the
CoRISpe project trying to encourage co-operation. The
CoRISpe electronic database allows remote data entry by
clinicians themselves and is password protected. The
confidentiality and security of the patients’ data are
strictly guarded and respected [15].
The structure
The CoRISpe consists of the Steering Committee,
Ethical Committee and two coordinators in the position
of directors whose responsibility is to guarantee the
correct performance of the CoRISpe. The Steering Com-
mittee represented by clinical researchers and participat-
ing institutions has created the basic regulations for the
Internal Organization of the CoRISpe and participates in
the scientific reviews of the procedures.
The Ethical Committee revises the agreements on the
patients’ consents and/or assents made with different
hospitals. All research projects presented in the CoRISpe
have to be approved by the Ethical Committee.
The CoRISpe also has a data manager responsible to
the Coordinators who clarifies any queries and gives
Figure 1 A. The number of HIV-infected children for each Autonomous Community is represented in the colours indicated. The highest
number of HIV-infected children can be seen in Catalonia, Madrid Community and Andalusia. B. Spanish: HIV-infected children born in Spain
parents: Immigrats: immigrants or the HIV-infected children of the immigrants.
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professional advice. To increase the quality of the dataset,
regular trips on a three-month basis are made by the data
manager to the hospitals participating in the CoRISpe.
The way the CoRISpe works
To provide data to the CoRISpe the parents or a legal
representative of an HIV-infected child must sign an
informed consent form in which the discomforts asso-
ciated with obtaining the clinical and laboratory data as
well as the research objectives are clearly explained. The
CoRISpe respects the Declaration of Helsinki, which
states that although parents or a legal representative of a
child sign the consent, a child is required to give her/his
assent for the participation in the study if s/he is able to
do so. If after having read the assent, a child decides
not to participate in the study, this decision must be
respected. These informed consent and assent forms must
be approved by the Ethical Committee. As a general rule,
the consent can be cancelled at any time [16,17].
All the participating hospitals send to the CoRISpe the
retrospective (since 1995) and prospective (since 2008)
dataset of the HIV-infected children, who fulfill the
inclusion criteria and have been in the clinical follow-up
through the online application. By the inclusion criteria
we understand: 1.The age – younger than 18 years old at
the moment of the diagnosis in the Paediatric Unit; 2.
The Diagnosis of the HIV infection confirmed; 3. The
predicted follow-up in the hospital and 4. The children
who have seen a paediatrician at least once since 1st of
January 1995. The follow-up visits of the children take
place every three months and are fixed by paediatricians.
There are records for teenagers and adults in the data-
base [18]. The follow-up of each child ends when a child
dies or changes to a no-CoRISpe hospital.
The electronic database applications have been
designed in accordance with the norms of data protec-
tion in force and guarantee the security access pursuant
to Ley Orgánica 15/1999, de 13 of December [15]. Each
paediatrician has an exclusive user account, which
enables the user to access her/his own data and to
update the data.
The CoRISpe, which is located in the Hospital General
Universitario Gregorio Marañon, provides a profound
quality internal control on a regular basis. The potential
errors of CoRISpe data are returned to each participat-
ing hospital for checking every 6 months. A specialised
agency carries out a CoRISpe external audition verifying
if the database information is in accordance with clinical
records of the HIV-infected patients. This audition is
performed annually on 10% of the clinical records in
each hospital.
Any researcher who is a member of the RED RIS [19]
or anyone who is in collaboration with a member can
apply for the CoRISpe dataset as long as the project is
scientifically, technically and ethically viable. A researcher
must complete a data release application to receive data.
This application must be submitted to the members of the
Steering Committee for an evaluation. If the project is
approved of, a researcher signs a release agreement with
the coordinators of the CoRISpe where the commitments
of both parts regarding the usage of information, criteria
of follow-ups, authorship and spread of results are stated.
The CoRISpe is responsible for supplying the dataset
needed to carry out projects. Once the above data have
been given, the principal researcher sends a scientific
report containing the project results once a year so that
the CoRISpe could keep updated records on all the pro-
jects. The CoRISpe does not charge any fee for providing
data to research groups.
There is a special authorship policy for publications as
well as for abstracts/ communication presented to the
congress and approved by the Steering Committee. Re-
gardless the amount of work each writer puts, s/he will
appear on the list of authors of a given article in propor-
tional turns among all the researchers of the participating
centres.
The CoRISpe organises a general meeting with the
Steering Committee and paediatricians from all the parts
of Spain once a year to evaluate the stage of the object-
ive and to plan new aims, projects, studies and numbers
of research. Also, the CoRISpe prepares professional
training, symposia, conferences and scientific fora.
Transition from paediatric to adults units
The criteria to establish the age of HIV-infected children to
be transferred to the Adult Units
The chronological and cognitive limits of the adolescent
period are unclear as there are several theoretical and
practical approaches [20]. WHO recognizes the adoles-
cent age as the period between 12 and 21 years. The
American Academy of Paediatrics between 13 and 21
years [21], whereas for the CDC adolescence lasts up to
the age of 24 [22]. In Spain, adolescence ends at the age
of 18 when an individual acquires legal autonomy.
The transfer of an adolescent suffering from a chronic
disease (heart disease, cystic fibrosis, diabetes) to the
Adult Unit is usually difficult [23-28]. Therefore, the
records stored by the transfer units of those adolescents
suffered from chronic diseases can be used as a point of
reference for the transfer units of HIV-infected children
taking into consideration the scarcity of data of the last
ones [20,21].
The way to obtain the dataset from the Adult Units
It is very important to know what happens with the
vertically HIV-infected children who have been
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Table 1 Demographic, immunological and virological profile of the vertically-HIV infected patients in the CoRISpe
Group A <18 years Group B ≥18 years Total
N=520 N=282 N=802
Age (years) mean (range) 12,6 (0,04-17,98) 22 (18,1-29,7) 15,1 (0,04-29,7)
Sex: N (%)
Male 241 (46,3) 127 (45) 368 (45,9)
Female 279 (53,7) 155 (55) 434 (54,1)
Origin: N (%)
Spain 353 (67,9) 261 (92,5) 614 (76,6)
Sub-Saharan Africa 102 (19,6) 7 (2,5) 109 (13,6)
Latin America 39 (7,5) 7 (2,5) 46 (5,7)
North Africa 10 (1,9) 3 (1,1) 13 (1,6)
East Europe 9 (1,7) 0 (0,0) 9 (1,1)
Asia 4 (0,8) 1 (0,3) 5 (0,6)
West Europe 3 (0,6) 3 (1,1) 6 (08)
Time of identification of infection
At Birth 79 (15,2) 11 (3,9) 90 (11,2)
After Birth (asymptomatic) 264 (50,8) 160 (56,7) 424 (52,9)
After Birth (symptomatic) 151 (29) 87 (30,9) 238 (29,7)
Unknown 26 (5) 24 (8,5) 50 (6,2)
Group age at 1st presentation (years)
<1 316 (60,8) 104 (36,9) 420 (52,3)
1-5 150 (28,8) 132 (46,8) 282 (35,2)
≥6 54 (10,4) 46 (16,3) 100 (12,5)
Group year of 1st presentation (years)
1975-1990 0 (0,0) 73 (25,9) 73 (9,1)
1991-2000 289 (55,6) 199 (70,6) 488 (60,8)
2001-2011 231 (44,4) 10 (3,5) 241 (30,1)
Group age at most recent follow-up visit (years)
0-5 70 (13,5) 0 (0,0) 70 (8,7)
6-11 209 (40,2) 0 (0,0) 209 (26,1)
12-17 241 (46,3) 0 (0,0) 241 (30)
≥18 0 (0,0) 282 (100) 282 (35,2)
CDC: N (%)
N-A 270 (51,9) 91 (32,3) 361 (45)
B 127 (24,4) 106 (37,6) 233 (29,1)
C 123 (23,7) 85 (30,1) 208 (25,9)
Co-infections: N (%)
HCV 24 (4,6) 31 (11) 55 (6,9)
HBV 7 (1,3) 3 (1,1) 10 (1,3)
CMV 19 (3,7) 3 (1,1) 22 (2,7)
Other 4 (0,8) 2 (0,7) 6 (0,7)
No Co-infections 466 (89,6) 243 (86,1) 709 (88,4)
Immunological status (%CD4) N (%)
<15% 9 (1,8) 20 (7,1) 29 (3,6)
15-25% 49 (9,4) 49 (17,4) 98 (12,3)
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transferred to the Adult Units. These vertically HIV-
infected adults have different social, psychological, clinical,
immunological, neurological and virological characteristics
from the patients infected by different ways [29-32]. To
obtain data from the Adult Units a paediatrician contacts
an adult clinician to explain the objective of the CoRISpe
and then their collaboration begins. A coordinator of the
CoRISpe contacts an adult clinician and requests him to
complete the online form.
Building efficient contacts between paediatricians, adult
clinicians and patients
In the first year the clinical contact between a paediatri-
cian and an adult clinician and a child who is in the
process of becoming an adult patient must be well estab-
lished to work efficiently. Very often the second year
brings confusion because a HIV-vertically infected adult,
not a child any more, is entitled to choose her/his doctor
and to change a hospital. At that moment the contact
between a paediatrician and a child is broken. In some
cases it is difficult to find an adult patient and match
her/his data with the data when s/he was a child. There-
fore, at present we have a low level of follow-up of verti-
cally infected young people once they are transferred to
the Adult Units.
General data
The entire population of HIV-1 infected children calcu-
lates for 1,100 to 1,200 in Spain. Up to now the CoRISpe
has recruited 838 patients. Some of the patients of 262-
362, which is a difference between 1,100-1,200 and 838
has not obtained the Ethical Committee approval and
some of them has not signed the inform consent because
they do not want to participate in the CoRISpe. Out of
838 patients 802 (95.7%) were vertically HIV-infected.
At this moment we cannot calculate the rate of loss-
to-follow-up of the coRISpe because we do not have
the number of dead patients and those who inter-
rupted the treatment. We are in the process of getting
the data from paediatricians. The data of the 802 verti-
cally HIV-infected patients included in the CoRISpe
are shown in the Table 1. Vertically HIV-infected
patients according to the year of birth and if the
patients were born in Spain or somewhere else
(Figure 1B).
We divided the 838 HIV-infected children into two
groups. The group A: 536 children <18 years old that had
a follow-up in the Paediatric Units. Out of 536 patients
520 (97%) were vertically HIV-infected of average 12.6
years old (range from 0.04 to 17.98 years old). 53.7% out
of 520 were girls. 353 (67.9%) out of 520 patients were
born in Spain from Spanish parents, 167 (32.1%) out of
520 were immigrants or the children of the immigrants
(Table 1). Fifty-four out of 520 (10.4%) children were also
co-infected by other viruses such us HCV, HBV or CMV.
The group B: 302 HIV-infected patients ≥18 years of
age were transferred to the Adult Units. Out of 302
HIV-infected patients 282 (93.4%) were vertically HIV-
infected of average 22 years old (range from 18.1 to 29.7
years old). 155 (55%) out of 282 were girls. The average
age of the patients followed up in the Adult Units was
2.38 years (range from 1.5 to 4.8 years old). 261 (92.5%)
were born in Spain from Spanish parents and only 7.5%
were immigrants or the children of the immigrants
(Table 1).
At the moment we are in the process of getting data from
the Adult Units as so far we have only been working with
the Pediatric Units. The antiretroviral treatment of only
484 children out of 520 has been available. In 21 HIV-
infected children the treatment was interrupted and 3 did
not receive any antiretroviral treatment. 460 patients out of
484 received the HAART. 225 (48.9%) patients received 2
nucleoside analogs and protease inhibitors. Moreover, 141
(30.7%) patients received 2 nucleoside analogs and 1
non analog, 42 (9.1%) patients 1 nucleoside analog, 1
nucleoside non analog and 1 protease inhibitor, 14 (3%)
patients took 3 nucleoside analogs, 24 (5.2%) patients
received various treatments including CCR5 enter
inhibitor or integrase inhibitors. Finally, 14 (3%)
patients took monotherapy with IPs. The most used
antiretroviral drugs in the CoRISpe were Lopinavir/r
(51.1%), 3TC (40%), ABV (39.1%) and FTC (30.2%) [13].
Table 1 Demographic, immunological and virological profile of the vertically-HIV infected patients in the CoRISpe
(Continued)
>25% 462 (88,8) 183 (64,9) 645 (80,4)
Unknown 0 (0,0) 30 (10,6) 30 (3,7)
Viral load (copies/ml) N (%)
<50 341 (65,6) 134 (47,5) 475 (59,2)
50-10000 92 (17,7) 83 (29,4) 175 (21,8)
>10000 27 (5,2) 36 (12,8) 63 (7,9)
Unknown 60 (11,5) 29 (10,3) 89 (11,1)
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It is important to point out that there is a close
co-operation between the CoRISpe and the Spanish
Paediatric HIV BioBank [16]. We have done seven re-
search projects with the data provided by the CoRISpe
and/or with the samples supplied by the BioBank. The
results of all these projects are available to the paediatri-
cians participating in the CoRISpe with a view to im-
proving the state of health of their patients [8,33-44].
Conclusions
To have the CoRISpe electronic database available has
been a very important issue in the research of vertically
HIV-infected children since the first years of the pan-
demic. We have a follow-up of the HIV-infected children
in the CoRISpe database of the Paediatric Units and we
have been working with these data obtaining interesting
results as it is seen in a great number of our published
articles [8,16,33-44]. Moreover, the CoRISpe has been
collaborating with different European Cohorts (EPPICC,
COHERE and PENTA) for many years.
The CoRISpe represents a novel approach to HIV
research that might be of general interest not only for
basic and clinical research teams working with HIV, but
also for those groups trying to establish large networks
focused on researching specific clinical problems. It also
represents a model to stimulate cooperative research on
specific clinical issues.
The main objective of this article has been to present
the notion of the CoRISpe, its role and to describe how
it works. The new exciting era of personalised medicine
is accompanied by the rise in the importance of the
databases and the biobanks. The quality of the data of
the CoRISpe, the number and quality of the samples
stored in the Spanish Paediatric HIV BioBank [16] are
required to fulfill the needs of personalised medicine. In
the coming years the databases and biobanks will repre-
sent the most important structures through which a high
number of researches in the majority of scientific fields
will be carried out.
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Consuegra, I; Díaz, L; Gallego, J; García-Alonso D; García-Merino, I; García, A;
Gómez, C; Jiménez, JL; Lorente, R; Muñoz- Fernández, MA (Director) and
Serramía, MJ.
Ethical principles referred to in this article are those expressed, for example,
in the Declaration of Helsinki published by the World Medical Association,
the United Nations’ Convention on the Rights of the Child, the Charter of
Fundamental Rights of the European Union (2000), the Universal Declaration
on Bioethics and Human Rights (UNESCO, 2005), the Universal Declaration
on the Human Genome and Human Rights (UNESCO, 1997), the
International Declaration on Human Genetic Data (UNESCO, 2003), the
Universal Declaration of Human Rights of 1948, the Council of Europe’s
Convention for the Protection of Human Rights and Dignity of the Human
Being with regard to the Application of Biology and Medicine: Convention
on Human Rights and Biomedicine, the Ley de Protección de Datos de
Caracter Personal (1999) and the Ley de Investigación Biomédica (2007).
These principles are also echoed and referred to in the ICH E guidelines on
Good Clinical Practice.
Additional information: The detailed description of patients recruited by the
CoRISpe can be found on its web http://www.retic-ris.net/. The coordinator
centre of the data of CoRISpe-1 is located in the Hospital General
Universitario Gregorio Marañón in Madrid and the CoRISpe-2 in Vall
d’Hebron, Barcelona. The information on how to get in touch with the
coordinators of the cohort can be found in the page before. The information
prepared and presented by the cohort is available for all the researchers of
the cohort on a permanent basis to help them to carry out their projects on
HIV infection.
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